The present invention refers to a combination of an eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and/or docosahexanoic acid (DHA), or a combination of a nutritional composition comprising EPA, DPA, and/or DHA and a protein, a carbohydrate, a fat, an amino acid, a fatty acid, a dietary fibre, a vitamin, a mineral, a trace element, ß-carotenoid, a flavonoid, a nucleotide, L- carnitin, choline, inositol, taurine, creatine, and/or a co-enzyme, wherein EPA is in an amount of 1 to 1000 mg/100ml, preferably 100 to 700 mg/100ml, DPA is in an amount of >50 mg/100ml, preferably 50 to 1000 mg/100ml, preferably 6 to 800 mg/100ml, more preferably 80 to 500 mg/100ml and/or DHA is in an amount of 1 to 500 mg/100ml, preferably 1 to 300 mg/100ml and a chemotherapeutic agent selected from the group consisting of an alkylating drug, an antimetabolite, an antimytotic cytostatic, a topoisomerase inhibitor, antitumor antibiotic, and any other cytostatic, and/or a radiotherapy. These combinations are successful for use in treating a neoplastic disease like the method for treating a neoplastic disease comprising EPA, DPA, and/or DHA or a nutritional composition comprising EPA, DPA, and/or DHA and and a protein, a carbohydrate, a fat, an amino acid, a fatty acid, a dietary fibre, a vitamin, a mineral, a trace element, ß-carotenoid, a flavonoid, a nucleotide, L- carnitin, choline, inositol, taurine, creatine, and/or a co-enzyme in combination with a chemotherapeutic agent, and/or radiotherapy.
